Investors might want to bet on Supernus Pharmaceuticals (SUPN), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically ...
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection to treat motor fluctuations in adults with advanced Parkinson’s disease ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
The FDA has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection, the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback